Navigation Links
Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
Date:9/30/2009

BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan. Under this purchase order, Sinovac is required to produce an additional 3 million doses of PANFLU.1 (15ug/0.5ml), Sinovac's H1N1 vaccine for the central government.

The 3 million dose purchase order announced today is in addition to the initial order for 3.3 million doses received from the Ministry of Industry and Information Technology of China on September 4, 2009. Sinovac is expected to complete the delivery of 4.5 million doses of PANFLU.1 to the Chinese central government by the end of October.

To date, more than 100,000 citizens in Beijing have been inoculated by PANFLU.1, Sinovac's H1N1 vaccine and no severe adverse events have been reported, demonstrating the good safety profile of Sinovac's H1N1 vaccine. In the vaccination campaign initiated in China, the side effects were monitored proactively through adverse events following immunization (AEFI).

Sinovac initiated production of the H1N1 vaccine on June 15, 2009 and initiated the clinical trial on July 22. On August 17, Sinovac announced its top-line positive results of the H1N1 vaccine clinical trials, in which the vaccine showed good safety and immunogenicity profiles after one shot. Following the positive results of an experts' evaluation conference organized by the State Food and Drug Administration (SFDA) on September 3, 2009, Sinovac obtained the production license from the SFDA for PANFLU.1, Sinovac's H1N1 vaccine.

Mr. Weidong Yin, Chairman, President and CEO of Sinov
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
2. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
3. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
4. Sinovac Reports Unaudited First Quarter 2009 Financial Results
5. Sinovac Schedules 2008 Annual General Meeting
6. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
7. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
8. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
9. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 "I ... beach because of her crutches," said an inventor from Wetumpka, ... the sights and sounds of the shore, I came up ... beach sand." , She created a prototype for the patent-pending ... The accessory enables the individual to use crutches, walkers, or ...
(Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
(Date:8/30/2014)... Seattle, WA (PRWEB) August 30, 2014 One ... of this era is the gluten-free diet. Originally meant for ... has become a catchall for people who are looking to ... gluten. However, not only is this kind of information erroneous, ... of health problems because of a drastic change in ...
(Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 The new ... Cure program was created by Karen Brimeyer, who wanted to ... world. , This guide is now easy to find ... instant download. In this guide, the author of the new ... cure. , Daily Gossip writes in its review that ...
(Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2
... heads to India to share his proven and simple strategies in ... Businesses. Long concerned and fascinated with India's obvious human and economical ... distressed businesses in slow economies. , ... Los Angeles, ...
... 15, 2008 A long-time microbial inhabitant of the human ... new study among more than 7,000 subjects led by NYU ... a bacterium that has co-existed with humans for at least ... Yet, kids between the ages of 3 and 13 are ...
... than 1500 nutritional supplements ... ... Creating Wellness Alliance,(CWA), experts in designing custom wellness programs for ... supplement,Vitalize. The announcement was made by biochemist, Lyle MacWilliam, author,of ...
... July 14 In response to the many,people who have ... Family,Trust" was set up today to help with Tony Snow,s ... as the Trustee with Tony Snow,s,three children, Kendall, Robbie and ... Snow Family Trust" by either sending a check,made payable to ...
... of American,Physicians, Inc. (CAP) today announced that its ... 10,000 member level truly represents a milestone for,our ... who founded,CAP more than 30 years ago were ... find a way to manage the escalating costs,of ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
Cached Medicine News:Health News:The Five Biggest Marketing Mistakes Made By Medical Offices and Small Businesses 2Health News:Stomach bug appears to protect kids from asthma, says NYU study 2Health News:Stomach bug appears to protect kids from asthma, says NYU study 3Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Approach to Blood ... Pressure Management, ... in the discovery and development of novel small,molecule therapeutics, announced ... statistically significant,blood pressure reductions in a Phase 2a study in ...
... MDVN ) today announced that data from an ... antagonist, MDV3100, will be presented,in an oral presentation at ... in Chicago., Session title: New Targeted Strategies ... time: Monday, June 2 at 11:30 a.m. Central Time ...
Cached Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
Medicine Products: